+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Urothelial Carcinoma Market 2020-2026

  • ID: 5148041
  • Report
  • August 2020
  • Region: United States
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
US Urothelial Carcinoma Market Size, Share & Trends Analysis Report by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others) and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

The US urothelial carcinoma market is estimated to grow modestly at a CAGR of around 9.6% during the forecast period. The US contributes significantly to the growth of the urothelial carcinoma treatment market in North America. The healthcare spending of the US is significantly high as compared to that of other regions. The US spends almost 17.2% of GDP on healthcare expenditure in 2018. Moreover, the investments in R&D and a surging pool of geriatric population coupled with a high prevalence of urothelial carcinoma is driving the market growth in the US. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060. Moreover, the US has the presence of some of the key players operating in the urothelial carcinoma market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.

US urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of urothelial carcinoma. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.

The companies which are contributing to the growth of the US urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the US urothelial carcinoma market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. US Urothelial Carcinoma Market Research and Analysis by Diagnosis
2. US Urothelial Carcinoma Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the US urothelial carcinoma market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the US urothelial carcinoma market.
  • Insights about market determinants which are stimulating the US urothelial carcinoma market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. US Urothelial Carcinoma Market by Diagnosis
5.1.1. Cystoscopy
5.1.2. Biopsy
5.1.3. Urinalysis
5.1.4. Urine Cytology
5.1.5. Intravenous Pyelogram (IVP)
5.1.6. Others (Biomarkers)
5.2. US Urothelial Carcinoma Market by Treatment
5.2.1. Surgery
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Others (Targeted Therapy)

6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. EMD Serono, Inc.
6.7. F. Hoffmann-La Roche Ltd.
6.8. Genentech Inc.
6.9. GlaxoSmithKline Plc
6.10. Johnson & Johnson Services, Inc.
6.11. Merck & Co., Inc.
6.12. Pfizer Inc.
6.13. Spectrum Pharmaceuticals, Inc.
6.14. Taris Biomedical LLC
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
Note: Product cover images may vary from those shown
Adroll
adroll